guten morgen an alle Schlafmützen !

IT&E International Reaffirms Positive Outlook for 4th Quarter Operating Results and Announces Strong Forecast for 2005
Thursday December 9, 8:30 am ET

SAN DIEGO--(BUSINESS WIRE)--Dec. 9, 2004--IT&E International Group (OTCBB:ITER - News), reaffirmed its positive outlook for the 4th quarter of 2004, citing a projected revenue increase in excess of 35% quarter over quarter, and expects to end the year with revenues increasing at least 35% for the second straight year. The company also announced that its projected operating guidance for 2005 is in the same 35-40% revenue growth range. In addition, the company announced several more positive developments in the furthering of its previously announced strategy to become one of the "Premier" companies in the Life Sciences Services Industry, and in the Pharmaceutical Services field.

Revenues for the fourth quarter of 2004 are expected to be in the $3.9-4.0 million range, with gross profit margins returning to historical levels of 32-33%. The company also expects to be Operating Income positive, Net Income positive and Cash Flow positive for the quarter and year to date.

On the subject of IT&E's continued execution of its corporate strategy, the company announces:

• Internal growth is once again expected to be at 35% or greater for the second straight year.
• The company's sales and business development pipeline is currently at an all time high.
• During the 4th quarter of 2004, new customer signings and preferred supplier relationships are at an all time high.
• Gross Profit margins have returned to historical levels, and are increasing.
• The company's balance sheet is strong, and the company has the required capital to continue to grow at the projected levels.
• The company plans to announce the appointment of outside Board Members, that in itself will confirm IT&E's position as a serious player in the regulatory compliance and CRO markets.
• The company's future acquisition strategy and outlook remains very positive.

"Since becoming a public company and beginning trading in June, 2004, IT&E has continually announced positive business fundamentals, growth, profitability, cash flow, outstanding new members of management and an opportunistic strategy in a growth industry. In light of these very positive things, the company's stock has recently declined significantly, and management is perplexed by these developments. It has just been brought to our attention that certain shareholders may be engaged in a sell-off of the company's stock, for which we can see no fundamental reason," says Peter Sollenne, Chief Executive Officer of IT&E International Group.

"I am extremely disappointed to see the recent decline in our stock price and understand the distress this event has placed on our loyal shareholders. At the same time, I am very pleased to be able to report that IT&E's business is sound. We are profitable with a 35%+ revenue growth rate and new business development signings at an all time high. We also continue to have in excess of an 80% repeat business rate with our existing customer base. In addition, our balance sheet is strong and our growth outlook is still extremely positive. We have continued to increase revenues, maintained a solid profit margin, positive cash flow, signed on several new key customers and secured renewals and extensions of major initiatives within existing clients. Further, the company is moving forward with its strategic acquisition strategy, and we are very encouraged about the prospects of closing a major acquisition over the next 3-4 months. The overall outlook for IT&E's continued financial growth is very positive as our pipeline for new customers is the strongest in the company's history. We will continue to move ahead on the execution of our strategic plans to raise additional capital to be used to make strategic acquisitions in the coming quarters, to become positioned as a premier Life Science Services company and become one of the Top 15-20 CRO organizations in the country," declares Sollenne.

IT&E focuses on providing leading pharmaceutical companies with project-based consulting services in the areas of data management, clinical programming, biostatistics and clinical validation. The company, with its talented team of industry veterans with many years of biopharma experience, utilizes the latest tools and procedures to help its clients move quickly and effectively through the FDA approval process. Its services range from providing patients for drug trials, skilled personnel for trials, enterprise software and training to manage data and ensure FDA compliance and validation of new pharmaceutical manufacturing facilities to biostatistics support and analysis, audits, contract research services, data entry and verification services and providing total clinical solutions that take companies completely through Phase IV clinical trials. The company's pharmaceutical, biotech, healthcare and other life science client list includes such well-known companies as Abbott Laboratories (NYSE:ABT - News), Amgen (NASDAQ:AMGN - News), Aventis Pasteur (NYSE:AVE - News), Baxter Pharmaceutical (NYSE:BAX - News), Bayer (NYSE:BAY - News), Bristol-Myers Squibb (NYSE:BMY - News), Chiron (NASDAQ:CHIR - News), Eli Lilly (NYSE:LLY - News), Genentech (NYSE:DNA - News), GlaxoSmithKline (NYSE:GSK - News), Novartis (NYSE:NVS - News), Pfizer (NYSE:PFE - News), Purdue Pharmaceuticals, Schering-Plough (NYSE:SGP - News), VaxGen (VXGN.PK), and Wyeth Global (NYSE:WYE - News).

Included in this release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to have been correct. The Company's actual results could differ materially from those anticipated in the forward-looking statements.